High-dose, Short-term Steroid and Low-dose Long-term Steroid Use in ARDS Caused by COVID-19

• Conditions: Short-term (3 Days) High-dose (1000 mg) Systemic Methylprednisolone

• Registration Number: NCT05047874
• Lead Sponsor: Biruni University

Brief Summary

In this study, we aimed to compare, retrospectively, the 15-day continuous hemodynamic, laboratory and clinical course of COVID 19 patients to whom we administered short-term (3 days) high-dose (1000 mg) systemic methylprednisolone with those to whom low-dose long-term (2x 40 mg) systemic methylprednisolone was administered.

Detailed Description

Not available

Study Timeline

• Status Verified: 2021-09
• Study First Submitted: 2021-09-16
• Study First Submitted QC: 2021-09-16
• Last Update Submitted: 2021-09-16
• Study First Posted: 2021-09-17
• Last Update Posted: 2021-09-17
• Study Start: 2021-09-20
• Primary Completion: 2021-10-20
• Study Completion: 2021-10-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Between June 1, 2020 and February 1, 2021, hospitalized in the General intensive care unit of Biruni University Medical Faculty Hospital with the diagnosis of COVID 19;
• patients over 18 years of age; (for the diagnosis of COVID 19; Identification of SARS-CoV-2 by reverse transcription-polymerase chain reaction (RT-PCR) in nasopharyngeal swab or sputum samples and Abnormal lung computed tomography finding (CT) scan finding with <90% oxygen saturation at rest (bilateral, subpleural, peripheral ground glass opacities)

Exclusion Criteria

• Patients with a diagnosis of steroid allergy or developing during treatment;
• pregnant or lactating women;
• Patients with active malignancy;
• Patients taking any immunosuppressive agent.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
C Reaktif Protein	15 DAYS	level of C Reaktif Protein

Trial Locations

Locations (1)

Ilke Kupeli; 🇹🇷 Istanbul, Turkey